Brooke Liang, Jingwei Zhao, Yongjun Kim, Keegan Q Barry-Holson, David B Bingham, Gregory W Charville, Teresa M Darragh, Ann K Folkins, Brooke E Howitt, Christina S Kong, Teri A Longacre, Austin J McHenry, Angus M S Toland, Xiaoming Zhang, Koeun Lim, Michelle J Khan, Dongkyun Kang, Eric J Yang
Demand for anal cancer screening is expected to rise following the recent publication of the ANCHOR trial, which showed that treatment of HSIL significantly reduces the rate of progression to anal cancer. While screening for HPV-associated squamous lesions in the cervix is well-established and effective, this is less true for other sites in the lower anogenital tract. Current anal cancer screening and prevention rely on high-resolution anoscopy (HRA) with biopsies. This procedure has a steep learning curve for providers and may cause patient discomfort...
April 12, 2024: Modern Pathology